LivaNova (NASDAQ:LIVN) Trading 13.8% Higher After Strong Earnings

Key Points

• Shares jumped 13.8% after LivaNova reported Q results that beat estimates—EPS $0.98 vs. $0.85 expected and revenue $362.3M vs. $346.05M—and the company set FY2026 guidance of $4.20–$4.30 EPS.
• Analysts are mixed but optimistic overall: the stock has a consensus rating of “Moderate Buy” with an average target of $74.78 and price targets ranging roughly from $66 to $85 (7 Buys, 2 Holds, 1 Sell).
• Key fundamentals show revenue up 14.3% YoY and a ROE of 16.54% despite a negative net margin of 17.46%; market cap is $3.62B and institutional ownership is very high at 97.64%.

LivaNova PLC (NASDAQ:LIVN - Get Free Report) shares traded up 13.8% on Wednesday following a stronger than expected earnings report. The stock traded as high as $65.97 and last traded at $65.5490. 225,348 shares traded hands during trading, a decline of 71% from the average session volume of 777,609 shares. The stock had previously closed at $57.59.

The company reported $0.98 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.85 by $0.13. The business had revenue of $362.30 million for the quarter, compared to the consensus estimate of $346.05 million. LivaNova had a positive return on equity of 16.54% and a negative net margin of 17.46%.The business's revenue was up 14.3% on a year-over-year basis. During the same period in the prior year, the business earned $0.88 earnings per share. LivaNova has set its FY 2026 guidance at 4.200-4.300 EPS.

Wall Street Analyst Weigh In

LIVN has been the subject of a number of recent analyst reports. The Goldman Sachs Group reaffirmed a "neutral" rating and issued a $66.00 price objective on shares of LivaNova in a research report on Friday, January 9th. Needham & Company LLC lifted their target price on LivaNova from $64.00 to $81.00 and gave the company a "buy" rating in a report on Wednesday, February 25th. Barclays lifted their target price on LivaNova from $67.00 to $73.00 and gave the company an "equal weight" rating in a report on Friday, February 27th. Piper Sandler reiterated an "overweight" rating and issued a $85.00 target price on shares of LivaNova in a report on Thursday, February 19th. Finally, Weiss Ratings reiterated a "sell (d+)" rating on shares of LivaNova in a report on Friday, March 27th. Seven equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $74.78.

Institutional Trading of LivaNova

Institutional investors and hedge funds have recently bought and sold shares of the company. Hantz Financial Services Inc. raised its stake in LivaNova by 159.9% during the fourth quarter. Hantz Financial Services Inc. now owns 434 shares of the company's stock valued at $27,000 after buying an additional 267 shares in the last quarter. State of Wyoming acquired a new stake in LivaNova during the second quarter valued at approximately $31,000. EverSource Wealth Advisors LLC raised its stake in LivaNova by 998.4% during the second quarter. EverSource Wealth Advisors LLC now owns 703 shares of the company's stock valued at $32,000 after buying an additional 639 shares in the last quarter. Quarry LP acquired a new stake in LivaNova during the third quarter valued at approximately $36,000. Finally, UMB Bank n.a. raised its stake in LivaNova by 63.0% during the third quarter. UMB Bank n.a. now owns 792 shares of the company's stock valued at $41,000 after buying an additional 306 shares in the last quarter. Institutional investors and hedge funds own 97.64% of the company's stock.

LivaNova Price Performance

The company has a 50 day simple moving average of $64.01 and a 200-day simple moving average of $61.94. The stock has a market cap of $3.62 billion, a price-to-earnings ratio of -14.94 and a beta of 0.82. The company has a quick ratio of 1.16, a current ratio of 1.36 and a debt-to-equity ratio of 0.29.

LivaNova Company Profile

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company's primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.